Preclinical CRO Market Report 2026

The preclinical cro market size has grown strongly in recent years. It will grow from $6.25 billion in 2025 to $6.84 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increasing pharmaceutical R&D investments, rising complexity of drug development pipelines, growing reliance on animal testing for safety validation, expansion of biotechnology research activities, increased regulatory scrutiny on preclinical data.

The preclinical cro market size is expected to see strong growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine research, rising focus on rare disease drug development, expansion of biologics and cell therapy pipelines, growing adoption of digital preclinical platforms, increasing partnerships between pharma companies and CROs. Major trends in the forecast period include increasing adoption of integrated preclinical study services, rising demand for advanced animal model expertise, growing outsourcing of early-stage drug development, expansion of regulatory-aligned toxicology capabilities, enhanced focus on data-driven study design.

The growing demand for preclinical trials is expected to drive the expansion of the preclinical CRO market in the coming years. Preclinical trials refer to studies conducted on medicines or treatments before they are tested in human volunteers. These studies often involve innovative medical devices, prescription drugs, and diagnostic products, with primary goals that include determining an initial safe dose for first-in-human studies and assessing potential toxicity. Preclinical trials are a vital component of the drug development process, and their significance continues to increase due to the heightened focus on ensuring the safety and effectiveness of new therapies. For instance, in February 2024, according to IQVIA, a US-based company operating across health information technology and clinical research, clinical development productivity improved in 2023, with a total of 69 novel active substances launched globally, representing six more launches than the previous year and including 24 first-in-class launches in the United States. Therefore, the rising demand for preclinical trials is fueling the growth of the preclinical CRO market.

Major companies operating in the preclinical CRO market are increasingly adopting advanced technologies to maintain their competitive position, such as disease biology knowledge graphs that enhance target identification and drug discovery in pharmaceutical research. A disease biology knowledge graph is a structured and comprehensive framework that maps relationships among genes, proteins, biological pathways, and disease phenotypes by integrating diverse biological datasets. This approach enables researchers to systematically investigate disease mechanisms, identify promising therapeutic targets, and accelerate drug discovery by providing a holistic view of disease biology. For instance, in February 2023, BenchSci, a Canada-based artificial intelligence solutions provider for preclinical research and development, launched ASCEND, an end-to-end software-as-a-service platform designed for preclinical drug discovery. By uncovering biological insights into the underlying mechanisms of disease, this platform aims to accelerate preclinical drug development pipelines. ASCEND leverages BenchSci’s machine-learning technology to extract experimental data from secure internal and public external sources and compares experimental outcomes using curated ontology datasets, enabling the generation of evidence-based maps of biological processes associated with various diseases.

In September 2024, PharmaLegacy Laboratories, a US-based preclinical drug development contract research organization, acquired BTS Research for an undisclosed amount. Through this acquisition, PharmaLegacy seeks to broaden its in vitro and in vivo preclinical service offerings, expand study capacity across North America, and enhance its global service capabilities. BTS Research is a US-based preclinical CRO that provides GLP and non-GLP biological services to pharmaceutical, biotechnology, medical device, and diagnostic clients.

Major companies operating in the preclinical cro market are Eurofins Scientific SE, WuXi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Laboratory Corporation Of America Holdings, Intertek Group plc, Crown Bioscience International, Cynbiose, AmplifyBio LLC, Vivotecnia SL, Altasciences Company Inc, Pharmaceutical Product Development LLC, Parexel International Corporation, Envigo RMS Holding Corporation, Veeda Clinical Research Ltd, ICON plc, Kunming Biomed International Ltd, PharmaLegacy Laboratories, NorthEast BioAnalytical Laboratories LLC, MDS Pharma Services, MPI Research, Toxikon Corporation, BioReliance Corporation, Covance Inc, Syngene International Limited.

North America was the largest region in the preclinical CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global preclinical CRO market during the forecast period. The regions covered in the preclinical cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preclinical cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the preclinical CRO market by increasing costs of imported laboratory instruments, analytical equipment, reagents, and specialized animal housing systems used in toxicology, bioanalysis, and pharmacology studies. Research-intensive regions such as North America and Europe are most affected due to dependence on globally sourced lab equipment, while Asia-Pacific faces higher operational costs for export-oriented CRO services. These tariffs are contributing to higher study costs and longer project timelines. However, they are also encouraging localized sourcing of lab supplies, expansion of domestic CRO infrastructure, and increased investment in regional research capabilities.

The preclinical cro market research report is one of a series of new reports that provides preclinical cro market statistics, including preclinical cro industry global market size, regional shares, competitors with a preclinical cro market share, detailed preclinical cro market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical cro industry. This preclinical cro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Preclinical contract research organizations (CROs) are support organizations that provide research and development expertise to help guide drug candidates through animal testing and advance them toward the clinical stage. A preclinical CRO assists medical product developers in demonstrating product safety and efficacy in living animal models that the US Food and Drug Administration considers to closely reflect human anatomy, prior to entering clinical trials or being applied in human care.

The primary services offered by preclinical CROs include bioanalysis and drug metabolism and pharmacokinetic (DMPK) studies, toxicology testing, compound management, chemistry, safety pharmacology, and others. A patient-derived organoid (PDO) is a small three-dimensional cell culture created from a patient’s cancer cells and has received significant investment and experimental validation for its potential to provide therapeutic insights for the diagnosis of complex diseases. The different types of preclinical CRO models include patient-derived organoid models and patient-derived xenograft models, which are available for both small and large animal studies. Model systems such as in vivo and in vitro are utilized by biopharmaceutical companies, government and academic institutions, medical device companies, and others.

The preclinical CRO market includes revenues earned by entities through project management, information gathering, medical evaluations, maximum dose research, adherence to regulations, efficacy and safety reporting, and quality analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.